Evidence map›Paper›PMID 35182233›Full record

ArticleHuman genetics2022

DVPred: a disease-specific prediction tool for variant pathogenicity classification for hearing loss.

Fengxiao Bu, Mingjun Zhong, Qinyi Chen, Yumei Wang, Xia Zhao, Qian Zhang, Xiarong Li, Kevin T Booth, Hela Azaiez, Yu Lu and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Human genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Rare disease genomics and precision medicine.Genomics & informatics · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Fengxiao Bu *Institute of Rare Diseases, West China Hospital of Sichuan University, Chengdu, 610000, China. bufengxiao@wchscu.cn.ORCID http://orcid.org/0000-0002-4882-4856
Mingjun Zhong *Institute of Rare Diseases, West China Hospital of Sichuan University, Chengdu, 610000, China.
Qinyi Chen *Medical Genetics Center, Southwest Hospital, Chongqing, 410078, China.
Yumei WangGeneDock Co.Ltd., Beijing, 100083, China.
Xia ZhaoGeneDock Co.Ltd., Beijing, 100083, China.
Qian ZhangInstitute of Rare Diseases, West China Hospital of Sichuan University, Chengdu, 610000, China.
Xiarong LiGeneDock Co.Ltd., Beijing, 100083, China.
Kevin T BoothDepartment of Neurobiology, Harvard Medical School, Boston, MA, 02246, USA.
Hela AzaiezMolecular Otolaryngology and Renal Research Laboratories, University of Iowa, Iowa City, IA, 52240, USA.
Yu LuInstitute of Rare Diseases, West China Hospital of Sichuan University, Chengdu, 610000, China.
Jing ChengInstitute of Rare Diseases, West China Hospital of Sichuan University, Chengdu, 610000, China.
Richard J H SmithMolecular Otolaryngology and Renal Research Laboratories, University of Iowa, Iowa City, IA, 52240, USA. richard-smith@uiowa.edu.
Huijun YuanInstitute of Rare Diseases, West China Hospital of Sichuan University, Chengdu, 610000, China. yuanhj301@163.com.
Sichuan University · CNAnnoroad Gene Technology (China) · CNUniversity of Iowa · USHarvard University · USSouthwest General Health Center · USSouthwest Hospital · CN

Funding

1 3 5 project for disciplines of excellence west china hospital, sichuan university ZYJC20002the national key research and development program of china 2017YFC0907503
6 · The paper itself

Abstract

Numerous computational prediction tools have been introduced to estimate the functional impact of variants in the human genome based on evolutionary constraints and biochemical metrics. However, their implementation in diagnostic settings to classify variants faced challenges with accuracy and validity. Most existing tools are pan-genome and pan-diseases, which neglected gene- and disease-specific properties and limited the accessibility of curated data. As a proof-of-concept, we developed a disease-specific prediction tool named Deafness Variant deleteriousness Prediction tool (DVPred) that focused on the 157 genes reportedly causing genetic hearing loss (HL). DVPred applied the gradient boosting decision tree (GBDT) algorithm to the dataset consisting of expert-curated pathogenic and benign variants from a large in-house HL patient cohort and public databases. With the incorporation of variant-level and gene-level features, DVPred outperformed the existing universal tools. It boasts an area under the curve (AUC) of 0.98, and showed consistent performance (AUC = 0.985) in an independent assessment dataset. We further demonstrated that multiple gene-level metrics, including low complexity genomic regions and substitution intolerance scores, were the top features of the model. A comprehensive analysis of missense variants showed a gene-specific ratio of predicted deleterious and neutral variants, implying varied tolerance or intolerance to variation in different genes. DVPred explored the utility of disease-specific strategy in improving the deafness variant prediction tool. It can improve the prioritization of pathogenic variants among massive variants identified by high-throughput sequencing on HL genes. It also shed light on the development of variant prediction tools for other genetic disorders.

Indexed as

DeafnessHearing LossGenomicsHigh-Throughput Nucleotide SequencingHumansVirulence

Identifiers

PMID35182233
OpenAlexW4213254761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.